Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod

The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's RHHBY Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System.
This singleplex test is the first real-time RT-PCR test to identify SARS-CoV-2 infection within 20 minutes, both asymptomatic and symptomatic persons.
The test will be available in July.
Price Action: RHHBY shares down 0.75% at $47.14 during the market trading session on the last check Friday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.